676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)

• Elizabeth Evans,
• Nagashree Seetharamu,
• Crystal Mallow,
• Maurice Zauderer,
• Barbara Burtness,
• Marya Chaney,
• Alexander Spira,
• Conor Steuer,
• Tarek Mekhail,
• J Thaddeus Beck,
• Douglas Adkins,
• Terrence Fisher,
• Amber Foster,
• John Leonard,
• Nabil F Saba,
• Megan Baumgart,
• Steven Hager,
• Christopher Chay

Affiliations

Elizabeth Evans

1Vaccinex, Rochester, NY, USA

Nagashree Seetharamu

2Northwell Health, Lake Success, NY, USA

Crystal Mallow

Aff42 grid.422076.5Vaccinex Rochester NY USA

Maurice Zauderer

3Vaccinex Inc., Rochester, NY, USA

Barbara Burtness

Aff8 grid.47100.320000000419368710Yale University School of Medicine New Haven CT USA

Marya Chaney

20Merck and Co., Inc, Kenilworth, NJ, USA

Alexander Spira

Department of Medical Oncology, Virginia Cancer Specialists, Fairfax, Virginia, USA

Conor Steuer

8Winship Cancer Institute of Emory University, Atlanta, GA, USA

Tarek Mekhail

The Cleveland Clinic, Cleveland, Ohio, USA

J Thaddeus Beck

7Highlands Oncology, Springdale, AR, USA

Douglas Adkins

Washington University School of Medicine, St. Louis, MO, USA

Terrence Fisher

1Vaccinex, Rochester, NY, USA

Amber Foster

1Vaccinex, Rochester, NY, USA

John Leonard

1Vaccinex, Rochester, NY, USA

Nabil F Saba

Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, Georgia, USA

Megan Baumgart

10University of Rochester, Rochester, NY, USA

Steven Hager

11California Cancer Associates for Research and Excellence, Inc, Fresno, CA, USA

Christopher Chay

12Messino Cancer Centers, Ashville, NC, USA